Strong evidence from independent research study illustrates Sensodetect’s ability to detect ADHD and Schizophrenia

A large independent study performed in University Hospital in Uppsala, Sweden has illustrated the validity of the SensoDetect technology (ABR profiling test).

The results show that patients with ADHD and Schizophrenia can be discriminated versus a healthy control group by using the SensoDetect technology. This is proven with very high sensitivity and specificity (Schizophrenia: Specificity 93,1% & Sensitivity 84,6%. ADHD: Specificity: 91,4% & Sensitivity 87,5%).

The main research team members are Chief Physician Eva Juselius Baghdassarian, Chief Physician Maria Nilsson Markhed and Chief Physician/Associate Professor Tommy Lewander and. Lewander is supervisor for the doctoral student work.

The conclusion of the research reads: “The ABR profiling tests discriminated schizophrenia and ADHD versus healthy controls with high sensitivity and specificity. The methods deserve to be further explored in larger clinical studies including a broad range of psychiatric disorders to determine their utility as potential diagnostic biomarkers.” 

SensoDetect’s CEO, Johan Olson comments: This is very strong evidence that SensoDetect’s technology can be used as a diagnostic aid for health care professionals. It also opens up to further broaden our potential market into other diagnoses other than ADHD and Schizophrenia.

These strong and very important results takes us one step closer in reaching our vision: “Improving the lives of people with mental disorders”. By using our technology as an aid, the lives of patients can be improved and the cost to society related to mental illness decreased. Jan Andersson, Chairman of the Board concludes.

The study is published in Acta Neuropsychiatrica:  

https://www.ncbi.nlm.nih.gov/pubmed/28803577

Johan Olson

CEO, SensoDetect Aktiebolag (publ)

Phone: +46 705 424600

e-mail: jo@sensodetect.com

 

Jan Andersson

Chairman of the board, SensoDetect Aktiebolag (publ)

Phone: +46 793 472280

E-mail: jan@sensodetect.com

SensoDetect highlights through patented equipment brain stem responses to audio stimuli in order to provide health care clear anomalies and patterns for use primarily within psychiatry. The goal is to increase efficiency in Psychiatry and thus the benefits for health care, society, patients and relatives.

Tags:

Subscribe

Quotes

This is very strong evidence that SensoDetect’s technology can be used as a diagnostic aid for health care professionals. It also opens up to further broaden our potential market into other diagnoses other than ADHD and Schizophrenia.
SensoDetect CEO, Johan Olson,
These strong and very important results takes us one step closer in reaching our vision: “Improving the lives of people with mental disorders”. By using our technology as an aid, the lives of patients can be improved and the cost to society related to mental illness decreased.
SensoDetect Chairman of the board, Jan Andersson